Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
Carlos Jiménez-VicenteAlexandra Martínez-RocaHelena PomaresSandra Castaño-DiezFrancesca GuijarroMònica López-GuerraAlex BatallerDaniel EstebanAlbert Cortés-BullichAmanda Isabel Pérez-ValenciaAres Guardia-TorrellesInés ZugastiMontserrat RoviraFrancesc Fernández-AvilésDolors ColomerMontserrat ArnanMarina Díaz-BeyáJordi EstevePublished in: Leukemia research (2023)